蒋先生获委任为行政总裁后，公司执行董事兼行政总裁许勇先生(“许先生”)已获调任为联席行政总裁，自2024年9月9日起生效。其执行董事职位维持不变。许先生将作为联席行政总裁，专注于管理及监督本集团于粤港澳大湾区的眼科服务和商务发展。Clear Medical (01406) issued an announcement. Mr. Wu Junda (“Mr. Wu”) has proposed to resign as a non-executive director of the company,...
Zhitong Finance App News, Clear Healthcare (01406) issued an announcement. Mr. Wu Junda (“Mr. Wu”) has proposed to resign as a non-executive director of the company, effective September 9, 2024, in order to invest more time in other personal and business development. Following his resignation, Mr. Wu has been appointed as a consultant to the company for a period of two years with effect from September 9, 2024.
Mr. Jiang Bo (“Mr. Jiang”) has been appointed as the Company's Executive Director and Chief Executive Officer with effect from September 9, 2024. As CEO, Mr. Jiang is responsible for the Group's overall management and business strategy formulation.
Following the appointment of Mr. Jiang as CEO, Mr. Xu Yong (“Mr. Xu”), the Company's executive director and chief executive officer, has been reassigned as Co-Chief Executive Officer with effect from September 9, 2024. Its position as executive director remains unchanged. As Co-CEO, Mr. Hsu will focus on managing and overseeing the Group's ophthalmology services and business development in the Guangdong-Hong Kong-Macao Greater Bay Area.
Mr. Ma Wai Hung (“Mr. Ma”) has proposed to resign as an independent non-executive director of the Company, effective September 9, 2024, in order to invest more time in other personal and business development.
Mr. Wang Can (“Mr. Wang”) has been appointed as an independent non-executive director of the Company with effect from September 9, 2024.
Following Mr. Wu's resignation as a non-executive director, he also resigned as a member of the Remuneration Committee with effect from September 9, 2024. After Mr. Sui Ma resigned as an independent non-executive director, he also resigned as the chairman of the company's remuneration committee, audit committee and nomination committee, with effect from September 9, 2024. Mr. Wang has been appointed by the board of directors as the Chairman of the Remuneration Committee, as a member of the Audit Committee and the Nomination Committee, with effect from September 9, 2024. Mr. Jiang has been appointed by the board of directors as a member of the Remuneration Committee with effect from September 9, 2024.
